F M Investments LLC Has $11.65 Million Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

F M Investments LLC lowered its stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 0.4% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 161,526 shares of the company’s stock after selling 590 shares during the quarter. F M Investments LLC owned about 0.33% of Prestige Consumer Healthcare worth $11,646,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Opal Wealth Advisors LLC bought a new position in Prestige Consumer Healthcare during the second quarter valued at about $26,000. Quest Partners LLC increased its position in shares of Prestige Consumer Healthcare by 2,826.7% during the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after purchasing an additional 424 shares during the period. EverSource Wealth Advisors LLC lifted its position in Prestige Consumer Healthcare by 80.6% in the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock worth $33,000 after purchasing an additional 208 shares during the period. Gladius Capital Management LP acquired a new stake in Prestige Consumer Healthcare during the second quarter worth $35,000. Finally, Northwestern Mutual Wealth Management Co. increased its holdings in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after buying an additional 433 shares during the period. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. DA Davidson increased their target price on shares of Prestige Consumer Healthcare from $93.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, August 28th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $94.20.

Prestige Consumer Healthcare Price Performance

Shares of Prestige Consumer Healthcare stock traded up $0.30 during midday trading on Friday, reaching $74.05. The company had a trading volume of 260,044 shares, compared to its average volume of 245,752. The company has a current ratio of 3.23, a quick ratio of 1.90 and a debt-to-equity ratio of 0.65. The stock has a fifty day simple moving average of $72.17 and a 200 day simple moving average of $69.56. Prestige Consumer Healthcare Inc. has a 1-year low of $56.61 and a 1-year high of $75.80. The company has a market capitalization of $3.67 billion, a price-to-earnings ratio of 18.11, a price-to-earnings-growth ratio of 2.08 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, August 8th. The company reported $0.90 EPS for the quarter, beating the consensus estimate of $0.86 by $0.04. The company had revenue of $267.10 million during the quarter, compared to analysts’ expectations of $260.54 million. Prestige Consumer Healthcare had a return on equity of 12.55% and a net margin of 18.43%. The business’s revenue for the quarter was down 4.4% on a year-over-year basis. During the same period last year, the firm earned $1.06 EPS. As a group, equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.43 earnings per share for the current year.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.